Clinical Trials Logo

Cardiac Amyloidosis clinical trials

View clinical trials related to Cardiac Amyloidosis.

Filter by:

NCT ID: NCT06201832 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Cardiac Amyloidosis in HFpEF Tunisian Patients

Amy-Card
Start date: July 1, 2023
Phase:
Study type: Observational

Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients. However, the diagnosis of CA is still challenging and requires multiple costly investigations. Regardless of the type of CA, TTR or AL, early diagnosis significantly improves prognosis. In this study, the investigators aimed to determine the prevalence of CA in Tunisian HFpEF patients and to identify clinical and ultrasound criteria predictive of CA.

NCT ID: NCT06197165 Not yet recruiting - Cardiac Amyloidosis Clinical Trials

AMYLO-SHIATSU-ACUTE-CHRONIC

AMYLO-SHIATSU
Start date: January 2024
Phase: N/A
Study type: Interventional

Demonstrate the beneficial impact of three targeted Shiatsu sessions versus "comfort" Shiatsu on symptoms in cardiac amyloidosis patients with severe symptoms. To demonstrate the beneficial short-term impact of a targeted SHIATSU session on neuro-cardio-vascular physiological parameters and symptoms in patients with cardiac amyloidosis compared with comfort Shiatsu and no Shiatsu. To demonstrate the beneficial impact of three targeted Shiatsu sessions versus "comfort" Shiatsu and no Shiatsu on symptoms (fatigue, sleep, pain, anxiety, depression dyspnea, digestive disorders, nausea) and quality of life in cardiac amyloidosis patients with severe symptoms. Evaluate patient satisfaction with shiatsu. Assess tolerance to shiatsu.

NCT ID: NCT06186167 Recruiting - AL Amyloidosis Clinical Trials

Amyloidosis Incidence in High-Risk Cardiac Device Patients

Start date: January 29, 2024
Phase:
Study type: Observational

This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a new, non-invasive diagnostic avenue for this condition.

NCT ID: NCT06175858 Not yet recruiting - Cardiac Amyloidosis Clinical Trials

Validation of Different Diagnostic Modalities in the Detection of Cardiac Amyloidosis Among Patients With "Red Flags"

Start date: January 2024
Phase: N/A
Study type: Interventional

The study aims to test and compare the diagnostic yield of different diagnostic modalities (speckle tracking echocardiography, CMR, serum and urine protein analysis and bone tracer scintigraphy) in the detection of cardiac amyloidosis among patients with "red flags" suspecting cardiac amyloidosis.

NCT ID: NCT06129656 Recruiting - Cardiac Amyloidosis Clinical Trials

Cardiac Amyloidosis Registry of University Hospital Leipzig

Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

This is a clinical registry of patients with cardiac amyloidosis being treated at University Hospital Leipzig. The aim of the registry is to collect detailed information about clinical events, symptoms, imaging, biomarkers, comorbidities, and treatment from routine patient management which would not be provided by randomized clinical trails.

NCT ID: NCT06129331 Recruiting - Aortic Stenosis Clinical Trials

Aortic Stenosis and Cardiac Amyloidosis

Start date: March 1, 2023
Phase:
Study type: Observational

The dual pathology of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized. Even tough efforts have been undertaken to bring cohorts together, the largest cohort of AS-ATTR to date is <50 patients. It is the aim of the present international, multi-center registry to collect ~300 patients with AS-CA creating a big enough cohort to allow 1. thorough characterization of this condition 2. assessment of log-term clinical outcomes of AS-CA 3. assessment of effectiveness of amyloid-specific treatment on top of valve replacement

NCT ID: NCT06096675 Recruiting - Cardiac Amyloidosis Clinical Trials

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

CAPACITY
Start date: January 22, 2024
Phase: N/A
Study type: Interventional

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.

NCT ID: NCT06034405 Recruiting - Clinical trials for Lumbar Spinal Stenosis

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Start date: September 19, 2023
Phase:
Study type: Observational

Primary objective: To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective. The specific aims of this epidemiologic investigation include: 1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at risk for ATTR cardiac amyloidosis. 2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue. The study will also explore the following: 1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining. 2. The prevalence of TTR deposits among subjects with amyloid as determined by mass spectrometry. 3. Evaluation of a novel artificial intelligence technique for that can identify amyloid histologically with standard H&E staining. 4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan (Tc99-PYP).

NCT ID: NCT05760287 Recruiting - Cardiac Amyloidosis Clinical Trials

Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study

Echo-AMY
Start date: December 9, 2022
Phase:
Study type: Observational

This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at our institution will be enrolled. The primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype. Secondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis ) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.

NCT ID: NCT05701410 Recruiting - Spinal Stenosis Clinical Trials

Prevalence of Cardiac Amyloidosis Among Patients With a History of Lumbar Spinal Stenosis.

CASS-I
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The study investigates the prevalence of cardiac amyloidosis among patients with a history of lumbar spinal stenosis within the last ten years in the region of central Denmark.